Congress fires another salvo at Allergan’s Mohawk deal; AI outfit raises $60M for discovery effort
→ Allergan’s move to try and steer around an IPR review of its patents for its $1.5 billion drug Restasis by handing them over to …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
